Shanghai Aohua Photoelectricity Endoscope Co., Ltd. (SHA:688212)
24.97
+0.26 (1.05%)
At close: Oct 19, 2026
SHA:688212 Revenue
Shanghai Aohua Photoelectricity Endoscope had revenue of 142.03M CNY in the quarter ending June 30, 2026, with 3.96% growth. This brings the company's total for the last twelve months to 793.05M, up 20.82% year-over-year. In the year 2025, Shanghai Aohua Photoelectricity Endoscope had annual revenue of 773.87M with 3.24% growth. That makes Shanghai Aohua Photoelectricity Endoscope the 21,347th largest company in the world by revenue and 3,916th in China.
Revenue (ttm)
793.05M
Revenue Growth
+20.82%
P/S Ratio
4.24
Revenue / Employee
707.45K
Employees
1,121
Market Cap
3.36B
Revenue by Geography
- China 455.50M 59.2%
- Overseas 313.38M 40.8%
Fiscal year ended Dec 31, 2025 See the full SHA:688212 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 773.87M | 24.32M | 3.24% |
| Dec 31, 2024 | 749.55M | 71.47M | 10.54% |
| Dec 31, 2023 | 678.08M | 232.82M | 52.29% |
| Dec 31, 2022 | 445.26M | 98.21M | 28.30% |
| Dec 31, 2021 | 347.05M | 83.77M | 31.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Kehua Bio-Engineering Co.,Ltd | 1.69B |
| Guangdong Biolight Meditech | 1.10B |
| Zhejiang Orient Gene Biotech | 1.01B |
| Ningbo David Medical Device | 584.68M |
| Nanjing Vishee Medical Technology | 478.71M |
| Medprin Regenerative Medical Technologies | 400.85M |
| Tellgen | 392.11M |
| Shanghai General Healthy Information and Technology | 371.61M |